Impact of the New EU HTA Regulation on Access to Innovative Medicines in Europe

Access to innovative medicines in Europe continues to be one of the major pending issues, especially considering the significant differences observed between countries. In recent years, the EU has developed a series of regulations that impact access. One of the most significant is the European Union Health Technology Assessment Regulation (EU HTA), aimed at addressing uneven access across the EU, among other goals.

Publications
Published on:
September 22, 2023
Chus Castillo

This new regulation will entail important changes for innovative companies. As part of #BIOSPAIN2023Interview initiative, Chus Castillo, Partner Consulting Iberia at Alira Health, spoke about the “Impact of the New EU HTA Regulation on Access to Innovative Medicines in Europe.”

Read Chus’ interview on AseBio’s website to get the latest updates on the HTA Regulation, related challenges, and its potential effect on access to innovative medicines.

Related news

Blog April 17, 2024
The Challenges for Medtech in a Complex Regulatory Landscape in 2024
Learn more about what manufacturers in the US and Europe should consider when developing their regulatory strategies and prioritizing their target markets from regulatory affairs expert Mercè Guerra.
Medical Devices MedTech Regulatory
Events March 25, 2024
Swiss Biotech Day 2024
We will sponsor, attend, and speak at Swiss Biotech Day. Don't miss our panel on strengthening ties to investors in uncertain times.
Biotech
Events February 22, 2024
Bio-Europe Spring
Connect with our biotech experts onsite in Barcelona at Bio-Europe Spring. How can we support your development plan and funding path?
Biotech
Events February 21, 2024
XXII Conferenza Nazionale Sulla Farmaceutica
Meet Giovanni Firenze, Partner Consulting Italy, onsite in Catania and learn more about the impact of the new AIFA reform.
Italy Regulatory
Blog February 21, 2024
The Importance of Involving Patients in the Health Technology Assessment Process for Rare Diseases
Experts Annabel de Maria and Ahmad Bechara share how engaging rare disease patients in the HTA process gives them the opportunity to have a meaningful impact.
Healthcare Technology Patient Engagement Rare Disease
Blog February 14, 2024
Biopharma in 2024: The Industry Outlook
Insights from recent J.P. Morgan Healthcare Conference including what's changed in biopharma since last year and what to expect this year.
Biopharma Biotech
Events February 1, 2024
2023 BioRegion Report Presentation
Biotech Spain
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.